Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Danaher, NeoGenomics, Exosome Diagnostics, and More

NEW YORK (GenomeWeb) – Qiagen said after the close of the market on Friday that it is transferring the US listing of its global shares to the New York Stock Exchange from the Nasdaq Global Market. The transfer is expected to be effective on or about Jan. 10, 2018. Qiagen's shares will continue to trade on the Nasdaq until the transfer is completed. The company's shares will continue to trade under the ticker "QGEN" after the transfer, and there will be no impact on the trading of Qiagen's global shares on the Frankfurt Stock Exchange under the ticker "QIA."

Danaher announced this week that its board has approved a regular quarterly dividend of $.14 per share, payable on Jan. 26, 2018 to shareholders of record on Dec. 29.

NeoGenomics this week signed an agreement with Thermo Fisher Scientific to join the Next-Generation Sequencing Companion Dx Center of Excellence Program, also referred to as COEP. NeoGenomics is one of the first laboratories to offer the newly FDA-approved Oncomine Dx Target Test for non-small cell lung cancer. This methodology allows rapid analysis of samples compared to previously approved testing approaches. NeoGenomics' Pharma Services Division supported the analytical validation of the Oncomine Dx Target Test for submission to the FDA.

Exosome Diagnostics said this week that it has inked an agreement for coverage of the ExoDx Prostate IntelliScore (EPI), its prostate cancer risk assessment test, with Three Rivers Provider Network (TRPN) of Chula Vista, California. TRPN — a managed care organization of medical doctors, hospitals, and other healthcare providers — provides healthcare benefits for more than 100 million patients in the US, and its network consists of more than 1.5 million provider locations and 200 payors, according to Exosome Diagnostics.

The US Preventive Services Task Force this week announced the release of its seventh annual report to congress, and highlighted five topics for which it said current evidence is insufficient for it to make a recommendation and for which more research is needed, including: screening for celiac disease; screening for obstructive sleep apnea in adults; screening for gynecologic conditions with pelvic examination; vision screening in children younger than three; and statin use for the primary prevention of cardiovascular disease in adults age 76 and older.

The report also identifies evidence gaps that prevent it from making recommendations for specific populations. They relate to screening for breast cancer in African-American women; screening for prostate cancer in African-American men; screening for illicit drug use in children and adolescents; and screening for hearing loss in older adults.

The Wellcome Trust Sanger Institute said this week that it plans to commemorate its 25th anniversary in 2018 by sequencing 25 new genomes of species in the UK.  Twenty of the species are divided into five categories: flourishing, floundering, dangerous, iconic, and cryptic. There are also five species chosen by the public.

In the first category, the institute will sequence the Grey Squirrel, the Ringlet Butterfly, the Roesel's Bush-Cricket, and the Oxford Ragwort. The floundering species are the Red Squirrel, the Water Vole, the Turtle Dove, and the Northern February Red Stonefly. The Giant Hogweed, the Indian Balsam, the King Scallop, and the New Zealand Flatworm make up the dangerous category. The iconic species are the Golden Eagle, the Blackberry, the European Robin, and the Red Mason Bee. And the cryptic species are the Brown trout, the Common Pipistrelle Bat, the Carrington’s Featherwort, and the Summer truffle. The public's chosen species are the Common Starfish, the Fen Raft Spider, the Lesser Spotted Catshark, the Asian Hornet, and the Eurasian Otter.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.